Drug Trial Radar · NCT01248494
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 2010
Primary completion
Dec 2012
Study completion May 2016
Sponsor
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase Ib multi-institution trial that evaluates the safety profile/tolerability and preliminary anti-tumor effect of BKM120 (a PI3K inhibitor) and endocrine therapy combination and BEZ235 (a PI3K/ mTOR inhibitor) and endocrine therapy combination in postmenopausal patients with hormone receptor-positive metastatic breast cancer.
Conditions
- Metastatic Breast Cancer
Interventions
BEZ235Drug
* Dose level 1: 400mg PO BID * Dose level -1: 400mg PO in AM and 200mg PO in PM * Dose level -2: 200mg PO BID
BKM 120Drug
* Dose Level 1: BKM120, 100 mg PO daily * Dose level -1: BKM120, 80 mg PO daily * Dose Level -2: BKM120, 60 mg PO daily
LetrozoleDrug
All levels: 2.5mg/day PO
BKM120Drug
* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly * Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly * Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose of BKM120 or BEZ235 given in combination with endocrine therapyTime frame: at 4 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Massachusetts General Hospital, Dana Farber Cancer Center
Boston, Massachusetts
Columbia University Medical Center
New York, New York
Vanderbilt Cool Springs
Nashville, Tennessee
Vanderbilt Breast Center One Hundred Oaks
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.